expression levels of CK5/6 (64%), CD44 (53%) and ER (91%) and high HER2/neu expression (53%) (p¼0.002). There was no association between the rate of expression of any of the markers and grade progression upon recurrence.
INTRODUCTION AND OBJECTIVES: Circular RNAs with a special form of non-coding RNAs play an important role in the development of human diseases, but few are known in various cancers. In the present study, we tried to explore the clinical application of circRNAs in bladder cancer.
METHODS: Sanger sequencing, divergent primer amplification and RNAse R digestion were used to identify existence of a novel circRNA (circLPAR1, hsa_circ_0087960) from deep sequencing of RNA for bladder cancer. It was detected in 146 cancer tissues and 20 cases paracancer tissues to compare the different expression by qRT-PCR. A univariate and multivariate Cox regression was carried out to explore the correlation between circLPAR1 expression level and the overall survival(OS) of patients. We further investigated the possible network for circRNA-miRNA-mRNA by bioinformatics analysis.
RESULTS: CircLPAR1 was composed of two exons with the size of 226bp. It was confirmed the objective existence and the circular structure, and first found to be significantly downregulated in bladder cancer tissues compared with paired paracancer tissues (P<0.001), which was verified by an external validation of other 60 pairs specimens(P¼0.0001). On the univariate and multivariate analysis for 146 patients, a low circRNA expression level (2 -?CT <0.0023) was significantly associated with poor OS compared to a high circRNA expression level (2 -?CT ¼0.0023), and the mean OS was 64.9 months and 87.6 months, respectively (P<0.001). Four miRNA (hsa-miR-762, hsa-miR323b-5p, hsa-miR-1183, hsa-miR-920 ) might be correlated with circL-PAR1 and circRNA-miRNA-mRNA interaction network was drawn.
CONCLUSIONS: Our findings suggested that circLPAR1(hsa_circ_0087960) might be a novel potential biomarker for the prognosis of bladder cancer and low expression of circLPAR1 indicated poor survival. has not yet demonstrated antitumor activity in muscle-invasive bladder cancer (MIBC). We hypothesized that an integrated approach to Her2 characterization in MIBC may better guide patient prioritization for targeted therapy.
Source of
METHODS: We investigated Her2 alterations on different biological levels (DNA, RNA and protein) in pre-chemotherapy MIBC of 127 patients who recieved at least 3 cycles of neoadjuvant chemotherapy prior to radical cystectomy (NAC cohort). The findings were underlined in the The Cancer Genome Atlas (TCGA) bladder dataset (n¼407). Moreover, the signifcance of Her2 was analysed between the recently identified molecular subtypes (TCGA clusters).
RESULTS: In the NAC cohort, FISH revealed that 16/83 tumors harbored ERBB2 amplification, while 24/127 had high Her2 protein expression by IHC (i.e. IHC score ¼ 3). Samples with ERBB2 amplification had higher mRNA (p<0.001) and protein expression (p<0.001). However, 6/16 amplified samples had mRNA expression in the 1st tertile, and 10/16 had IHC scores of either 1 (n¼5) or 2 (n¼5). Interestingly, epigenetic regulation may downregulate Her2 expression. ERBB2 amplified tumors with low mRNA and protein expression showed a high ERBB2 methylation rate (R¼-0.62, p<0.001). While the vast majority of ERBB2 amplified tumors (37/41), showed amplification of other known oncogenes (e.g. CCND1, CCDE1), 4 tumors showed 'exclusively' ERBB2 amplification.In both datasets, Her2 alterations were most frequent in TCGA cluster I. None of the Her2 alterations harbored prognostic information in the TCGA dataset. In the NAC dataset, Her2 was a marker of unfavourable outcome in tumors assigned to TCGA cluster I. INTRODUCTION AND OBJECTIVES: Germline copy number polymorphisms (CNPs) are expected to affect various diseases including human malignancies, but the significance of CNPs in nonmuscle invasive bladder cancer (NMIBC) remains unclear. PCSK6 is reported to regulate proliferation and tumor progression in breast and prostate cancer, and affect sodium homeostasis. The purpose of this study is to determine the prognostic value of CNPs for NMIBC. To our knowledge, this is the first report to confirm CNPs as a potential biomarker for assessing the prognosis of NMIBC.
METHODS: Array comparative genomic hybridization (CGH) was performed to search for candidate CNPs related to NMIBC susceptibility. Next, quantitative real-time polymerase chain reaction was carried out to evaluate for CNPs related to patient's outcome in 190 NMIBC.
RESULTS: Eleven CNPs were associated with NMIBC risk in array CGH. FAM81A and PCSK6 copy number according to those CNPs examined showed significant relationship with recurrence and disease progression in NMIBC. Patients with pT1 stage had significantly lower PCSK6 copy number than those with pTa (P ¼ 0.0258). Interestingly, patients with lower PCSK6 copy number had significantly higher sodium levels in the blood than those with higher PCSK6 copy number (P ¼ 0.0144). Univariate Cox proportional hazards regression analysis showed that tumor grade (P ¼ 0.0073), pT stage (P ¼ 0.0086), Cytology (P ¼ 0.0045), FAM81A (P ¼ 0.0173), and PCSK6 (P ¼ 0.0011) copy number had a significant effect on progression-free survival. In multivariate analyses, PCSK6 copy number was an independent prognostic factor for progression-free survival (P ¼ 0.0380, risk ratio 2.25, 95% confidence interval 1.05-5.03).
CONCLUSIONS: These data suggest that PCSK6 CNP is potentially a new tumor marker for estimating the prognosis of NMIBC.
Source of Funding: none

MP44-10 ROLE OF MOLECULAR CLASSIFICATION IN HIGH GRADE (HG) NON MUSCLE INVASIVE BLADDER CANCER(NMIBC)
Marina G andara-Cort es, Manuel Carballo-Quinta*, María Elena L opez-Díez, María Pilar San Miguel-Fraile, Jos e Antonio Ortiz-Rey, M aximo Castro-Iglesias, C G omez de María, Sheila Domínguez-Alm uster, Miguel P erez-Schoch, Joaquín Gonz alez-Carrer o, Vigo, Spain INTRODUCTION AND OBJECTIVES: There has been a growing interest in urothelial bladder cancer, probably due to new treatment modalities that will require molecular phenotyping. In order to tackle this issue, the aim of this study is to identify cases of HG-NMIBC at higher risk, by using the recently developed molecular classification of HG urotelian tumours: basal and luminal type.
METHODS: We retrospectively analyzed data from 70 patients with primary or recurrent T1G3 NMIBC. All patients underwent complete transurethral resection of the bladder tumor including muscle in the sample. Every case received BCG induction. The study protocol (cod 2015/072) received approval from the ethics committee of clinical investigation of Galicia (Spain). Written informed consent was gained from all alive patients. Pathology specimens were reviewed by two independent investigators. Immunohistochemistry with prediluted antibodies against CD44 (Clone SP37), CK20 (Clone SP33), all of them from Ventana, and a concentrated antibody antiCK5 (Clone XM26, Novocasta) were used for categorized NMIBC as Luminal (CK5 and CD44 negative, CK20 positive) and Basal (CK5, CD44 positive and CK20 negative). Data were analyzed using SPSS version 19.0 for Windows IBM, Chicago, USA. A p value <0.05 was considered statistically significant.
RESULTS: 76 % of cases (51/67) were categorized as Luminal and 3% (2/67) as Basal. Only 20.9% of cases (14/67) were not classifiable due to inconclusive test. Recurrence rate was lower in Luminal group (33%), compared with the basal group (50%). This differences do not reach statistical significance. Progression rate was lower in Luminal group (12%) compared with Basal group (50%), without statistical significance CONCLUSIONS: Immunohistochemistry is useful for molecular classification of HR-NMIBC in luminal and basal types. In our study, most of HG-NMIBC belonged to the luminal type group. Given that cases in the basal group has presented a worse clinical outcome, and due to the availability of targeted treatment already used for other tumors, larger studies are needed to elucidate the role of this markers in the follow up and treatment for HG-NMIBC tumors. METHODS: mRNA expression of HA-family and EMT genes (beta-catenin, Twist, and Snail) in 72 bladder tissue specimens (28 normal; 44 tumor); follow-up: 20.3+/-2.5 months, was measured by QPCR. The effect of 4-MU (0-0.6 mM) on cell growth, apoptosis, HAsignaling were examined in BCa cell lines by Q-PCR, immunoblotting, proximal ligation and PI-3K activity assays. Effect of oral administration of 4-MU (100, 200-mg/kg) on tumor growth was analyzed in preclinical models.
RESULTS: HAS-1, -2 -3, HYAL-1 and Snail levels were 10-20-fold elevated in BCa tissues as compared to normal bladder (P<0.001). In univariate analysis, HAS-1, -2, HYAL-1 and Twist levels correlated with metastasis (P<0.001); HYAL-1 was an independent predictor of metastasis. 4-MU inhibited cell proliferation, chemotactic motility and invasion in a dose-dependent manner; 50-70% inhibition at IC50 (0.4 mM) for HA-synthesis inhibition. 4-MU induced apoptosis (>3-fold) via the death receptor pathway. 4-MU downregulated HA-signaling; mRNA and/or protein levels of CD44, RHAMM, p-Akt, beta-catenin, p-betacatenin(S552), snail and twist were downregulated by 3-5-fold, but pßcatenin((T41/S45), pGSK-3alpha/beta and E-cadherin levels were elevated. 4-MU also inhibited CD44/PI-3K complex formation and PI-3K activity. HA addition or mAkt expression attenuated 4-MU effects. In xenograft studies, 4-MU oral treatment abrogated growth of established
